Home Financial Markets Penny Stocks Genfit SA (GNFT): Recent Developments Show Potential, Soared 145% After-Market

Genfit SA (GNFT): Recent Developments Show Potential, Soared 145% After-Market

Shares of drugmaker Genfit SA (GNFT) soared after the ring of the bell on Tuesday. In the after-market session, the stock added more than 145% to its value reaching $13.00.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.  

Shares of the company gained by 0.95% during the regular session on Tuesday trading as high as $5.38 while $5.13 remained the day’s low. During the trading session, a total of 0.97 million shares were traded which represents a 1214.53% rise from the average session volume which is 73.63K shares. GNFT had ended its last session trading at $5.29.


The 2021 Backdoor Crypto Portfolio (free)

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.

Sponsored


Read More

What the company do?

GENFIT is a late-stage biopharmaceutical firm devoted to changing the life of cholestatic and metabolic chronic liver disease patients. With a long tradition and deep research legacy spanning more than two decades, GENFIT is a leader in the area of nuclear receptor-based drug development. GENFIT is currently participating in ELATIVE, a Phase 3 clinical trial in patients with primary biliary cholangitis testing elafibranor (PBC). Elafibranor is an investigational drug that has not yet been reviewed by any regulatory body and has not obtained clearance.

Recent Developments:

Yesterday, the company announced the publication of positive Phase 2 clinical results of elafibranor in the Journal of Hepatology in patients with Primary Biliary Cholangitis (PBC) who did not respond to ursodeoxycholic acid.

These results confirm our rationale for looking at elafibranor as a novel treatment for PBC and convince us that a pivotal Phase 3 trial is imperative, said CMO of Genfit, Dr. Carol Addy. PBC remains a disease with unmet medical needs, partly because a substantial number of patients have inadequate responses to existing treatments or cannot benefit from them, she added.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.  

What’s next for elafibranor?

The Food and Drug Administration (FDA) categorized elafibranor as Breakthrough Therapy based on the Phase 2 data. Additionally, the European Medicines Agency (EMA) classified it as an Orphan Drug. GENFIT has begun recruiting patients for the pivotal Phase 3 clinical trial ELATIVE to investigate the safety and effectiveness of elafibranor among patients with PBC and insufficient response to UDCA.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

Why Did The CMCL Stock Rise By 8% In Last Trading?

Caledonia Mining Corporation Plc (NYSE: CMCL) gained 8.91% during the trading session on Thursday. The share price reached a low of $13.70 and a...

Why Progyny Inc (PGNY) stock gained on Thursday, April 15?

Progyny Inc (PGNY) stock gained 7.31% in the after-hours session on Thursday, April 15, 2021, after it gained 0.94% in the early session.  PGNY...

Here is Dolphin Entertainment Inc (DLPN) stock turnaround on Thursday, April 15, 2021

Dolphin Entertainment Inc (DLPN) stock was facing negativity in the normal trading session on Thursday, April 15, 2021. It lost 8.05% in the morning...

Why Is TAOP Stock Increasing Today?

Taoping Inc. (NASDAQ: TAOP) is rising on the charts today with a gain of 18.04% to trade at $7.33 at last check-in early trading. Yesterday,...

Is VIZSF Stock Price Up This Past Session?

At the previous close, shares of Vizsla Silver Corp. (OTCQB: VIZSF) were up 8.41% to $1.41. A total of 201,300 shares of Vizsla Silver...

How Did The KXIN Stock Rise In The Last Session?

On Thursday, more than 15.02 million shares of Kaixin Auto Holdings (NASDAQ: KXIN) were traded, and the closing share price was $2.56, an increase...

Why Did The CMCL Stock Rise By 8% In Last Trading?

Caledonia Mining Corporation Plc (NYSE: CMCL) gained 8.91% during the trading session on Thursday. The share price reached a low of $13.70 and a...

What Led The AKUS Stock To Increase On Thursday?

In its Thursday trading session, Akouos Inc. (NASDAQ: AKUS) rose by 8.08%, or $1.16, compared with its previous market close price. The lowest price...

Related News

What Happened On Thursday To Make MMEX Stock Drop?

MMEX Resources Corporation (OTCPink: MMEX) closed yesterday at $0.00135, a drop of -6.90%. The volume of trading for MMEX stock was 302.59M which was...

ALPP Stock Fell 8% On Thursday, Why?

The leading operator and owner of small market businesses, Alpine 4 Holdings, Inc. (OTCQBX: ALPP) closed Thursday's regular trading session at $3.24 a share,...

Did Anything Boost HCMC Stock Last Trading?

On Thursday, shares of Healthier Choices Management Corp. (OTCPink: HCMC) gained 4.5%, touching a low of $0.0011 and a high of $0.0012. In the...

Why Did ENZC Stock Plummet In Last Trading?

Enzolytics Inc. (OTCPINK: ENZC) has been trading in a $0.1133 to $0.1435 range, closing its last trading day down -4.73 percent at $0.1248. Enzolytics...

Do You Know Why ABML Stock Dropped 4% On Thursday?

American Battery Metals Corporation (OTCQB: ABML) stock lost -4.35% on the last trading session when the stock closed at $1.32.  An American Battery Metals...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get The Best Stocks To Trade Every Day!...100% Free

We do not sell or share your information with anyone.

Get Best Morning Financial Newsletter... 100% Free

Best stocks ideas

Analysts’ Upgrades & Downgrades

Insider Watchlist

Important Earnings

We do not sell or share your information with anyone.